clinical trial · NCT07414394
Tigulixostat (IBI128) vs Febuxostat in Gout
Innovent Biologics Technology Limited (Shanghai R&D Center)·phase3·recruiting·n = 600
GoutFebuxostatTigulixostat
brief summary
The primary purpose of this study is to compare the efficacy of Tigulixostat (IBI128) versus Febuxostat on the proportion of Chinese adults with gout achieving a serum uric acid (sUA) level \< 360 μmol/L at Week 24. The study also evaluates safety, gout attacks, kidney function, inflammation, and quality of life over 52 weeks of treatment. Approximately 600 eligible participants will be randomized to receive either Tigulixostat or Febuxostat.
started
Mar 17, 2026
primary completion
Apr 30, 2027
completion
Oct 30, 2027
last updated
Mar 25, 2026
official title
A Randomized, Double-Blind, Double-Dummy, Multi-Center, Phase III Study Comparing the Efficacy and Safety of Tigulixostat (IBI128) and Febuxostat in Chinese Subjects With Gout
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol